Polaryx Therapeutics Inc. Common Stock
PLYX | NASDAQ
$1.76
+$0.01 (+0.57%)
Nov 2, 2026, 3:46 PM ET · Market open
TTM Period Ending | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 | Q4 2025 Dec 31, 2025 | Q3 2025 Sep 30, 2025 | Q1 2025 Mar 31, 2025 | Q4 2024 Dec 31, 2024 |
|---|---|---|---|---|---|---|
Net Income | -6.85M | -5.47M | -7.98M | -7.21M | -5.78M | -723K |
Depreciation & Amortization | n/a | n/a | n/a | n/a | n/a | n/a |
Stock-Based Compensation | 575K | 575K | 4.56M | 4.65M | 4.54M | 87K |
Other Working Capital | -117K | -295K | -20K | -3K | -100K | -9K |
Other Non-Cash Items | 270K | 437K | 57K | n/a | n/a | n/a |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | n/a |
Change in Working Capital | 195K | 17K | 275K | 103K | -332K | -224K |
Operating Cash Flow | -5.81M | -4.44M | -3.09M | -2.46M | -1.57M | -860K |
Capital Expenditures | n/a | n/a | n/a | n/a | n/a | n/a |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | n/a | n/a | n/a | n/a | n/a | n/a |
Sales Maturities Of Investments | n/a | n/a | n/a | n/a | n/a | n/a |
Other Investing Acitivies | n/a | n/a | n/a | n/a | n/a | n/a |
Investing Cash Flow | n/a | n/a | n/a | n/a | n/a | n/a |
Debt Repayment | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | 9.68M | -156K | -156K | -156K | n/a | n/a |
Financial Cash Flow | 14.05M | 4.22M | 4.47M | 6.33M | 3M | 2.75M |
Net Cash Flow | 8.24M | -224K | 1.38M | 3.87M | 1.43M | 1.89M |
Free Cash Flow | -5.81M | -4.44M | -3.09M | -2.46M | -1.57M | -860K |
Adj. Free Cash Flow | -6.38M | -5.02M | -7.65M | -7.1M | -6.11M | -947K |
Maintenance CapEx | n/a | n/a | n/a | n/a | n/a | n/a |
Growth CapEx | n/a | n/a | n/a | n/a | n/a | n/a |
Owner Earnings | -5.81M | -5.15M | -3.95M | n/a | n/a | n/a |
Add to Watchlist
Select watchlists to add or remove PLYX